A detailed history of Cambridge Advisors Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Cambridge Advisors Inc. holds 8,775 shares of ABBV stock, worth $1.56 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares
8,775
Previous 8,840 0.74%
Holding current value
$1.56 Million
Previous $1.52 Million 14.25%
% of portfolio
0.39%
Previous 0.36%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$163.84 - $199.33 $10,649 - $12,956
-65 Reduced 0.74%
8,775 $1.73 Million
Q2 2024

Jul 11, 2024

BUY
$154.79 - $180.76 $10,061 - $11,749
65 Added 0.74%
8,840 $1.52 Million
Q1 2024

Apr 16, 2024

SELL
$159.82 - $182.1 $95,892 - $109,260
-600 Reduced 6.4%
8,775 $1.6 Million
Q4 2023

Jan 16, 2024

SELL
$137.6 - $154.97 $27,520 - $30,994
-200 Reduced 2.09%
9,375 $1.45 Million
Q3 2023

Oct 18, 2023

SELL
$133.59 - $154.65 $67,462 - $78,098
-505 Reduced 5.01%
9,575 $1.43 Million
Q2 2023

Jul 13, 2023

SELL
$132.51 - $164.9 $143,773 - $178,916
-1,085 Reduced 9.72%
10,080 $1.36 Million
Q1 2023

Apr 13, 2023

BUY
$144.61 - $166.54 $7,230 - $8,327
50 Added 0.45%
11,165 $1.78 Million
Q4 2022

Jan 23, 2023

SELL
$138.31 - $165.87 $48,408 - $58,054
-350 Reduced 3.05%
11,115 $0
Q3 2022

Oct 17, 2022

SELL
$134.21 - $153.93 $6,710 - $7,696
-50 Reduced 0.43%
11,465 $1.54 Million
Q2 2022

Jul 18, 2022

SELL
$137.62 - $174.96 $32,065 - $40,765
-233 Reduced 1.98%
11,515 $1.76 Million
Q1 2022

May 05, 2022

SELL
$131.98 - $163.75 $4,883 - $6,058
-37 Reduced 0.31%
11,748 $1.9 Million
Q4 2021

Jan 14, 2022

BUY
$107.43 - $135.93 $42,972 - $54,372
400 Added 3.51%
11,785 $1.6 Million
Q3 2021

Oct 19, 2021

SELL
$106.4 - $120.78 $24,578 - $27,900
-231 Reduced 1.99%
11,385 $1.23 Million
Q2 2021

Jul 21, 2021

SELL
$105.21 - $117.21 $28,827 - $32,115
-274 Reduced 2.3%
11,616 $1.31 Million
Q1 2021

Apr 22, 2021

BUY
$102.3 - $112.62 $102 - $112
1 Added 0.01%
11,890 $1.29 Million
Q4 2020

Jan 25, 2021

BUY
$80.49 - $108.67 $80 - $108
1 Added 0.01%
11,889 $1.27 Million
Q3 2020

Oct 15, 2020

BUY
$85.91 - $100.83 $171 - $201
2 Added 0.02%
11,888 $1.04 Million
Q2 2020

Jul 17, 2020

BUY
$73.37 - $98.18 $73 - $98
1 Added 0.01%
11,886 $1.17 Million
Q1 2020

Apr 21, 2020

BUY
$64.5 - $97.79 $33,862 - $51,339
525 Added 4.62%
11,885 $906,000
Q4 2019

Jan 28, 2020

SELL
$72.13 - $90.25 $28,852 - $36,100
-400 Reduced 3.4%
11,360 $1.01 Million
Q3 2019

Oct 25, 2019

SELL
$62.98 - $75.72 $3,778 - $4,543
-60 Reduced 0.51%
11,760 $890,000
Q1 2019

Apr 16, 2019

SELL
$77.14 - $90.79 $3,857 - $4,539
-50 Reduced 0.42%
11,820 $953,000
Q4 2018

Jan 29, 2019

BUY
$77.85 - $96.01 $7,784 - $9,601
100 Added 0.85%
11,870 $1.09 Million
Q3 2018

Oct 24, 2018

SELL
$88.91 - $98.84 $26,673 - $29,652
-300 Reduced 2.49%
11,770 $1.11 Million
Q1 2018

Apr 18, 2018

SELL
$92.01 - $123.21 $24,382 - $32,650
-265 Reduced 2.15%
12,070 $1.14 Million
Q3 2017

Oct 27, 2017

BUY
$69.85 - $89.22 $861,599 - $1.1 Million
12,335
12,335 $1.1 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Cambridge Advisors Inc. Portfolio

Follow Cambridge Advisors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Advisors Inc. with notifications on news.